What We're Reading: Page
Industry reads hand-picked by our editors
Jul 20, 2026
-
Axios
How AI is supercharging drug development
-
The Financial Times
AstraZeneca highlights rare diseases in $80bn revenue push
-
Chemical & Engineering News
Access to potential long COVID drugs dwindles as trials falter
-
CNBC
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Jul 17, 2026
-
NPR
TrumpRx promised a supermarket for cheaper drugs but delivered a boutique
-
BioSpace
FDA’s first AI-focused cGMP warning letter signals new scrutiny for manufacturers
-
The Washington Post
CDC, FDA link Taco Bell lettuce supplier to multistate cyclosporiasis outbreak
-
MIT Technology Review
There’s a lot of hype around perimenopause. Don’t buy it.
Jul 16, 2026
-
The Economist
Eli Lilly is reinventing the pharma business
-
Bloomberg
Kalshi Will Offer Sports-Style Betting on Drug Trial Results
-
The Washington Post
CDC nominee says she won’t betray science — and also backs Kennedy’s actions
-
BioCentury
Nearly 40% of this year’s Asia-to-West NewCos are aiming at first in class
Jul 15, 2026
Jul 14, 2026
Jul 13, 2026
-
The Financial Times
AstraZeneca CEO: ‘Biology will catch up with me at some point’
-
CNBC
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
-
NBC News
Dozens hospitalized with cyclosporiasis as cases of gastrointestinal illness spike in 31 states
Jul 10, 2026
-
The Wall Street Journal
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
-
The Atlantic
The Genes That Could Cancel Out a Fatal Diagnosis
-
Bloomberg
Biotech M&A Surge Seen as Going Beyond Blockbuster Deals